NL-OMON55667招募中4 期
ong Term Follow-up after Primary or Revision Shoulder Arthroplasty with a Patient- specific Glenius Implant: A prospective case series - Glenius study
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •patients having primary or revision shoulder joint replacement with severe
- •glenoid bone defects caused by: (1) Non-inflammatory degenerative joint disease
- •including osteoarthritis and avascular necrosis, (2) Inflammatory degenerative
- •joint disease such as rheumatoid arthritis; (3) Congenital malformations,
- •posttraumatic deformities or removal of components during revision surgery
- •Patient is 18 years of age or older
- •Patient can follow the Glenius system procedure that is standard of care and
- •according to the appropriate Glenius system instructions for use.
- •Patient has participated in the informed consent process and has signed the
- •EC approved informed consent form
排除标准
- •Pregnant patients
- •Skeletally immature patients
- •Prisoners
研究者
相似试验
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 14.0Level: PTClassification code 10019641Term: Hepatic cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2006-006529-25-DESchering-Plough Research Institute1,954
进行中（未招募）
不适用
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis CEUCTR2006-006529-25-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,800
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 8.1Level: LLTClassification code 10019641Term: Hepatic cirrhosisEUCTR2006-006529-25-NLSchering-Plough Research Institute1,954
已完成
3 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C.Chronic Hepatitis CHepatitis C virus infection10047438NL-OMON35269Schering-Plough9
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis C. - NDEUCTR2006-006529-25-ITSCHERING-PLOUGH1,954